Download PDF
CC BY 4.0 · TH Open 2022; 06(03): e267-e275
DOI: 10.1055/a-1897-7061
Original Article

Saddle Pulmonary Embolism in Patients with Cancer in the Era of Incidental Events: Clinical Findings and Outcomes in a Single Centre Cohort

Mario Aramberri 
1   Department of Internal Medicine, Hospital de Galdakao-Usansolo, Galdakao, Spain
,
Mariana Benegas
2   Department of Radiology, Hospital Clinic de Barcelona, Barcelona, Spain
,
Marcelo Sanchez
2   Department of Radiology, Hospital Clinic de Barcelona, Barcelona, Spain
,
Diego Muñoz-Guglielmetti
3   Department of Radiation Oncology, Barcelona, Spain
,
Carles Zamora
4   Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain
,
Adrián García-Villa
5   Department of Internal Medicine, Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain
,
Carmen Diaz-Pedroche
6   Department of Internal Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain
,
Carme Font
4   Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Background There is scarce information regarding the prevalence and clinical impact of saddle pulmonary embolism (PE) in patients with cancer.

Objectives This study aimed to assess the prevalence, clinical findings, and short-term outcomes of patients with cancer-related saddle PE including acute symptomatic and unsuspected events.

Patients/Methods Consecutive patients with cancer-related PE (March 1, 2006–October 31, 2014) were retrospectively reviewed by a chest radiologist to assess PE burden and signs of right ventricular (RV) overload. The clinical outcomes within 30 days were evaluated according to saddle versus nonsaddle PE.

Results Thirty-six (12%) out of 289 patients with newly diagnosed cancer-related PE presented with saddle PE. Saddle PE was found in 21 cases (58%) with acute symptomatic PE and the remaining 15 cases (42%) were found as unsuspected findings. Patients with saddle PE had more frequently experienced a previous thrombotic event (31 vs. 13%; p = 0.008), and it occurred more frequently as an acute symptomatic event (58 vs. 39%; p = 0.025) compared with those with nonsaddle PE. Signs of RV overload including RV/left ventricle ratio ≥1 (22 vs. 4%; p < 0.001) and interventricular septum displacement (53 vs. 20%; p < 0.001) were also more common in patients with saddle PE compared with nonsaddle PE. Overall, PE-related mortality, venous thromboembolism recurrence, and major bleeding within 30 days were found to be similar according to saddle versus nonsaddle PE.

Conclusion Saddle PE is not uncommon in patients with cancer-related PE including in those with unsuspected PE. Similar 30-day outcomes were found according to saddle versus nonsaddle PE in our cohort.

Keywords

cancer - incidental findings - pulmonary embolism - thrombosis - venous thromboembolism

Note

This work has been partially reported at the following medical meetings: ISTH Virtual Congress 2020 (July 12–14, 2020), 10th ICTHIC VIRTUAL EDITION (April 22–24, 2021).




Publication History

Received: 23 May 2022

Accepted: 04 July 2022

Accepted Manuscript online:
12 July 2022

Article published online:
14 December 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
    CrossrefPubMedGoogle Scholar
  • 2 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71 (01) 7-33
    CrossrefPubMedGoogle Scholar
  • 3 Desai SR. Unsuspected pulmonary embolism on CT scanning: yet another headache for clinicians?. Thorax 2007; 62 (06) 470-472
    CrossrefPubMedGoogle Scholar
  • 4 Di Nisio M, Ferrante N, De Tursi M. et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010; 104 (05) 1049-1054
    PubMedGoogle Scholar
  • 5 Font C, Farrús B, Vidal L. et al. Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Ann Oncol 2011; 22 (09) 2101-2106
    CrossrefPubMedGoogle Scholar
  • 6 Moser KM, Fedullo PF, LitteJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994; 271 (03) 223-225
    CrossrefPubMedGoogle Scholar
  • 7 Dentali F, Ageno W, Becattini C. et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res 2010; 125 (06) 518-522
    CrossrefPubMedGoogle Scholar
  • 8 Di Nisio M, Lee AYY, Carrier M, Liebman HA, Khorana AA. Subcommittee on Haemostasis and Malignancy. Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost 2015; 13 (05) 880-883
    CrossrefPubMedGoogle Scholar
  • 9 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
    CrossrefPubMedGoogle Scholar
  • 10 Meyer HJ, Wienke A, Surov A. Incidental pulmonary embolism in oncologic patients-a systematic review and meta-analysis. Support Care Cancer 2021; 29 (03) 1293-1302
    CrossrefPubMedGoogle Scholar
  • 11 van der Hulle T, den Exter PL, Planquette B. et al. Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J Thromb Haemost 2016; 14 (01) 105-113
    CrossrefPubMedGoogle Scholar
  • 12 den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 2011; 29 (17) 2405-2409
    CrossrefPubMedGoogle Scholar
  • 13 Caiano L, Carrier M, Marshall A. et al. Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost 2021; 19 (10) 2468-2479
    CrossrefPubMedGoogle Scholar
  • 14 Key NS, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update summary. J Oncol Pract 2019; 15 (12) 661-664
    CrossrefPubMedGoogle Scholar
  • 15 Stevens SM, Woller SC, Baumann Kreuziger L. et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST Guideline and expert panel report. Chest 2021; 160 (06) 2247-2259
    CrossrefPubMedGoogle Scholar
  • 16 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
    CrossrefPubMedGoogle Scholar
  • 17 Bova C, Sanchez O, Prandoni P. et al. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. Eur Respir J 2014; 44 (03) 694-703
    CrossrefPubMedGoogle Scholar
  • 18 Donzé J, Le Gal G, Fine MJ. et al. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost 2008; 100 (05) 943-948
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000; 84 (04) 548-552
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Meinel FG, Nance Jr JW, Schoepf UJ. et al. Predictive value of computed tomography in acute pulmonary embolism: systematic review and meta-analysis. Am J Med 2015; 128 (07) 747-59.e2
    CrossrefPubMedGoogle Scholar
  • 21 Enzweiler CNH, Wiese TH, Lembcke AE. et al. Electron beam tomography of interpulmonary saddle embolism: extent and vascular distribution. J Comput Assist Tomogr 2002; 26 (01) 26-32
    CrossrefPubMedGoogle Scholar
  • 22 Gandara E, Bose G, Erkens P, Rodgers M, Carrier M, Wells P. Outcomes of saddle pulmonary embolism: a nested case-control study. J Thromb Haemost 2011; 9 (04) 867-869 DOI: 10.1111/j.1538-7836.2011.04189.x.
    CrossrefPubMedGoogle Scholar
  • 23 Brown TJ, Khan SA. Large saddle embolus during cancer therapy. BMJ Case Rep 2016; 2016: bcr2016215837
    CrossrefPubMedGoogle Scholar
  • 24 Nobis A, Sierko E, Kasprowicz B, Jelski S, Wojtukiewicz MZ, Sierko E. Massive saddle pulmonary embolism during radiochemotherapy of head and neck cancer. Pol Arch Intern Med 2017; 127 (7-8): 561-563
    CrossrefPubMedGoogle Scholar
  • 25 Kelly JM. Incidental finding of asymptomatic saddle pulmonary embolism in a patient with poorly differentiated signet ring cell adenocarcinoma. d63. Pulmonary Embolism: Case Reports and Late Breaking 2020; 201: A7259
    PubMedGoogle Scholar
  • 26 Singh D, Foessel R, Nagra N, Lau P, Brauchli D. Acute saddle pulmonary embolism on 18F-FDG PET/CT: diagnosis by functional imaging. Respirol Case Rep 2019; 7 (08) e00476
    CrossrefPubMedGoogle Scholar
  • 27 Font C, Carmona-Bayonas A, Fernández-Martinez A. et al. Outpatient management of pulmonary embolism in cancer: data on a prospective cohort of 138 consecutive patients. J Natl Compr Canc Netw 2014; 12 (03) 365-373
    CrossrefPubMedGoogle Scholar
  • 28 Font C, Carmona-Bayonas A, Beato C. et al; Asociación para la Investigación de la Enfermedad Tromboembólica de la región de Murcia. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. Eur Respir J 2017; 49 (01) 1600282
    CrossrefPubMedGoogle Scholar
  • 29 Peris M, Jiménez D, Maestre A. et al; RIETE Investigators. Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. Eur Respir J 2016; 48 (05) 1360-1368
    CrossrefPubMedGoogle Scholar
  • 30 Gladish GW, Choe DH, Marom EM, Sabloff BS, Broemeling LD, Munden RF. Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history. Radiology 2006; 240 (01) 246-255
    CrossrefPubMedGoogle Scholar
  • 31 Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol 2007; 189 (01) 162-170
    CrossrefPubMedGoogle Scholar
  • 32 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 33 Prentice A, Ruiz I, Weeda ER. Saddle pulmonary embolism and in-hospital mortality in patients with cancer. Int J Clin Oncol 2019; 24 (06) 727-730
    CrossrefPubMedGoogle Scholar
  • 34 Banala SR, Yeung SJ, Rice TW. et al. Discharge or admit? Emergency department management of incidental pulmonary embolism in patients with cancer: a retrospective study. Int J Emerg Med 2017; 10 (01) 19
    CrossrefPubMedGoogle Scholar
  • 35 Kwak MK, Kim WY, Lee CW. et al. The impact of saddle embolism on the major adverse event rate of patients with non-high-risk pulmonary embolism. Br J Radiol 2013; 86 (1032): 20130273
    CrossrefPubMedGoogle Scholar
  • 36 Nahidi SM, Ali U, Duka L, Fuentes-Rosales JC, Bhatt U. Incidental finding of saddle pulmonary embolism on a CT scan of the abdomen and pelvis in a patient with adenocarcinoma of the colon. Cureus 2021; 13 (12) e20757
    PubMedGoogle Scholar
  • 37 Musani MH. Asymptomatic saddle pulmonary embolism: case report and literature review. Clin Appl Thromb Hemost 2011; 17 (04) 337-339
    CrossrefPubMedGoogle Scholar
  • 38 Yusuf SW, Gladish G, Lenihan DJ. et al. Computerized tomographic finding of saddle pulmonary embolism is associated with high mortality in cancer patients. Intern Med J 2010; 40 (04) 293-299
    CrossrefPubMedGoogle Scholar
  • 39 Alkinj B, Pannu BS, Apala DR, Kotecha A, Kashyap R, Iyer VN. Saddle vs nonsaddle pulmonary embolism: clinical presentation, hemodynamics, management, and outcomes. Mayo Clin Proc 2017; 92 (10) 1511-1518
    CrossrefPubMedGoogle Scholar
  • 40 Ryu JH, Pellikka PA, Froehling DA, Peters SG, Aughenbaugh GL. Saddle pulmonary embolism diagnosed by CT angiography: frequency, clinical features and outcome. Respir Med 2007; 101 (07) 1537-1542
    CrossrefPubMedGoogle Scholar
  • 41 Sardi A, Gluskin J, Guttentag A, Kotler MN, Braitman LE, Lippmann M. Saddle pulmonary embolism: is it as bad as it looks? A community hospital experience. Crit Care Med 2011; 39 (11) 2413-2418
    CrossrefPubMedGoogle Scholar
  • 42 Pruszczyk P, Pacho R, Ciurzynski M. et al. Short term clinical outcome of acute saddle pulmonary embolism. Heart 2003; 89 (03) 335-336
    CrossrefPubMedGoogle Scholar
  • 43 Hajizadeh R. Short term mortality of patients with saddle pulmonary embolism: a single center study. Turk Kardiyol Dern Ars 2021; 47 (03) 273-280
    PubMedGoogle Scholar
  • 44 Stein PD, Matta F, Hughes MJ. Effects of thrombolytic therapy in low-risk patients with pulmonary embolism. Am J Cardiol 2021; 139: 116-120
    CrossrefPubMedGoogle Scholar
  • 45 Barco S, Mahmoudpour SH, Planquette B, Sanchez O, Konstantinides SV, Meyer G. Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2019; 40 (11) 902-910
    CrossrefPubMedGoogle Scholar